==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1200 which contains 4 entries.


Entry 1
(1) Primary information
ID1806
ThPP IDTh1200
Therapeutic Peptide/Protein NameProthrombin complex concentrate
SequenceNA view full sequnce in fasta
Functional ClassificationIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeFactor II - 48-60 hrs; factor VII - 1.5-6 hrs; factor IX - 20-24 hrs and factor X - 24 - 48 hrs.
DescriptionAnti-inhibitor coagulant complex, also known as activated prothrombin complex concentrate (APCC) is a preparation containing precursor and activated forms of blood coagulation factors II, VII, IX, and X derived from pooled human venous plasma.
Indication/DiseaseFor use in hemophilia A and B patients with inhibitors for: 1) control and prevention of bleeding episodes; 2) perioperative management; and 3) Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
PharmacodynamicsThe administration of human prothrombin complex provides an increase in plasma levels of the vitamin K dependent coagulation factors, and can temporarily correct the coagulation defect of patients with deficiency of one or several of these factors.
Mechanism of ActionThey act by reversal of anticoagulants
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameFeiba Nf
CompanyBaxter Healthcare Corporation
Brand DiscriptionFEIBA (Anti-Inhibitor Coagulant Complex) is a freeze-dried sterile human plasma fraction with factor VIII inhibitor bypassing activity to be reconstituted for intravenous administration. Factor VIII inhibitor bypassing activity is expressed in arbitrary units. One unit of activity is defined as that amount of FEIBA that shortens the aPTT of high titer factor VIII inhibitor reference plasma to 50% of the blank value.
Prescribed forNA
Chemical NameNA
FormulationNA
Physcial AppearanceFreeze-dried fraction
Route of AdministrationIntravenous
Recommended DosageDo not exceed a single dose of 100 units per kg body weight and a daily dose of 200 units per kg body
ContraindicationKnown anaphylactic or severe hypersensitivity reactions to FEIBA or any if its components, including factors of the kinin generating system. Disseminated intravascular coagulation (DIC). Acute thrombosis or embolism (including myocardial infarction).
Side EffectsThe most frequently reported adverse reactions observed in > 5% of subjects in the prophylaxis trial were anemia, diarrhea, hemarthrosis, hepatitis B surface antibody positive, nausea, and vomiting. The serious adverse reactions seen with FEIBA are hypersensitivity reactions and thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.
Useful Linkhttp://www.rxlist.com/feiba-vh-drug/side-effects-interactions.htm
PubMed ID28124406, 27367551, 26677005, 26509839, 25705417, 25586208, 25485923, 25136597, 24934756
3-D StructureN.A.


Entry 2
(2) Primary information
ID1807
ThPP IDTh1200
Therapeutic Peptide/Protein NameProthrombin complex concentrate
SequenceNA view full sequnce in fasta
Functional ClassificationIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeFactor II - 48-60 hrs; factor VII - 1.5-6 hrs; factor IX - 20-24 hrs and factor X - 24 - 48 hrs.
DescriptionAnti-inhibitor coagulant complex, also known as activated prothrombin complex concentrate (APCC) is a preparation containing precursor and activated forms of blood coagulation factors II, VII, IX, and X derived from pooled human venous plasma.
Indication/DiseaseFor use in hemophilia A and B patients with inhibitors for: 1) control and prevention of bleeding episodes; 2) perioperative management; and 3) Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
PharmacodynamicsThe administration of human prothrombin complex provides an increase in plasma levels of the vitamin K dependent coagulation factors, and can temporarily correct the coagulation defect of patients with deficiency of one or several of these factors.
Mechanism of ActionThey act by reversal of anticoagulants
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameCofact
CompanySanquin
Brand DiscriptionNA
Prescribed forCo-fact©, prothrombin complex concentrate, is used for restoring the international normalized ratio (INR) in patients on vitamin K antagonists (VKA) presenting with acute bleeding.
Chemical NameNA
FormulationNA
Physcial AppearanceNA
Route of AdministrationIntravenous
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Linkhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655866/
PubMed ID28124406, 27367551, 26677005, 26509839, 25705417, 25586208, 25485923, 25136597, 24934756
3-D StructureN.A.


Entry 3
(3) Primary information
ID1808
ThPP IDTh1200
Therapeutic Peptide/Protein NameProthrombin complex concentrate
SequenceNA view full sequnce in fasta
Functional ClassificationIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeFactor II - 48-60 hrs; factor VII - 1.5-6 hrs; factor IX - 20-24 hrs and factor X - 24 - 48 hrs.
DescriptionAnti-inhibitor coagulant complex, also known as activated prothrombin complex concentrate (APCC) is a preparation containing precursor and activated forms of blood coagulation factors II, VII, IX, and X derived from pooled human venous plasma.
Indication/DiseaseFor use in hemophilia A and B patients with inhibitors for: 1) control and prevention of bleeding episodes; 2) perioperative management; and 3) Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
PharmacodynamicsThe administration of human prothrombin complex provides an increase in plasma levels of the vitamin K dependent coagulation factors, and can temporarily correct the coagulation defect of patients with deficiency of one or several of these factors.
Mechanism of ActionThey act by reversal of anticoagulants
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameKcentra
CompanyCsl Behring Ag
Brand DiscriptionKcentra is a purified, heat-treated, nanofiltered and lyophilized non-activated four-factor Prothrombin Complex Concentrate (Human) prepared from human U.S. Source Plasma (21 CFR 640.60). It contains the Vitamin K dependent Coagulation Factors II, VII, IX and X, and the antithrombotic Proteins C and S. Factor IX is the lead factor for the potency of the preparation as stated on the vial label. The excipients are human antithrombin III, heparin, human albumin, sodium chloride, and sodium citrate. Kcentra is sterile, pyrogen-free, and does not contain preservatives.
Prescribed forKcentra, (Prothrombin Complex Concentrate (Human)), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.
Chemical NameNA
FormulationNA
Physcial AppearanceNanofiltered and lyophilized non-activated four-factor Prothrombin Complex Concentrate
Route of AdministrationIntravenous
Recommended DosageReconstitute Kcentra with 20 mL of diluent (Sterile Water for Injection, USP) provided with the kit. When reconstituted, the final concentration of drug product in Factor IX units will be in a range from 20-31 units/mL, depending on the actual potency, which is listed on the carton.
ContraindicationPatients with known anaphylactic or severe systemic reactions to Kcentra or any components in Kcentra including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and Human albumin. Patients with disseminated intravascular coagulation (DIC). Patients with known heparin-induced thrombocytopenia (HIT). Kcentra contains heparin
Side EffectsThe most common adverse reactions (ARs) (frequency ≥ 2.8%) observed in subjects receiving Kcentra were headache, nausea/vomiting, arthralgia, and hypotension. The most serious ARs were thromboembolic events including stroke, pulmonary embolism, and deep vein thrombosis. Other include Hypersensitivity Reactions; Arterial and venous thromboembolic complications; Possible Transmission of Infectious Agents.
Useful Linkhttp://www.rxlist.com/kcentra-drug.htm
PubMed ID28124406, 27367551, 26677005, 26509839, 25705417, 25586208, 25485923, 25136597, 24934756
3-D StructureN.A.


Entry 4
(4) Primary information
ID1809
ThPP IDTh1200
Therapeutic Peptide/Protein NameProthrombin complex concentrate
SequenceNA view full sequnce in fasta
Functional ClassificationIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeFactor II - 48-60 hrs; factor VII - 1.5-6 hrs; factor IX - 20-24 hrs and factor X - 24 - 48 hrs.
DescriptionAnti-inhibitor coagulant complex, also known as activated prothrombin complex concentrate (APCC) is a preparation containing precursor and activated forms of blood coagulation factors II, VII, IX, and X derived from pooled human venous plasma.
Indication/DiseaseFor use in hemophilia A and B patients with inhibitors for: 1) control and prevention of bleeding episodes; 2) perioperative management; and 3) Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
PharmacodynamicsThe administration of human prothrombin complex provides an increase in plasma levels of the vitamin K dependent coagulation factors, and can temporarily correct the coagulation defect of patients with deficiency of one or several of these factors.
Mechanism of ActionThey act by reversal of anticoagulants
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameOctaplex
CompanyOctapharma
Brand DiscriptionNA
Prescribed forTreatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. Treatment of bleeding and perioperative prophylaxis in congenital deficiency of the vitamin K dependent coagulation factors II and X when purified specific coagulation factor product is not available.
Chemical NameNA
FormulationNA
Physcial AppearancePowder and solvent for solution
Route of AdministrationIntravenous
Recommended DosageThe dose will depend on the INR before treatment and the targeted INR. In the following table approximate doses (ml/kg body weight of the reconstituted product) required for normalisation of INR (≤ 1.2 within 1 hour) at different initial INR levels are given
ContraindicationIn patients with acquired deficiency of the vitamin K dependent coagulation factors (e.g. as induced by treatment with vitamin K antagonists), Octaplex should only be used when rapid correction of prothrombin complex levels is necessary, such as major bleeding or emergency surgery. In other cases, reduction of the dose of the vitamin K antagonist and/or administration of vitamin K is usually sufficient. Patients receiving a vitamin K antagonist may have an underlying hypercoaguable state and infusion of prothrombin complex concentrate may exacerbate this. In congenital deficiency of any of the vitamin K dependent factors, specific coagulation factor product should be used when available. If allergic or anaphylactic-type reactions occur, the infusion should be stopped immediately. In case of shock, standard medical treatment for shock should be implemented.
Side EffectsImmune system disorders; General disorders and administration site conditions; Vascular disorders; Nervous system disorders;
Useful Linkhttps://www.medicines.org.uk/emc/medicine/21897
PubMed ID28124406, 27367551, 26677005, 26509839, 25705417, 25586208, 25485923, 25136597, 24934756
3-D StructureN.A.